azacitidine and Leukemia, Myelomonocytic, Chronic

azacitidine has been researched along with Leukemia, Myelomonocytic, Chronic in 131 studies

Research

Studies (131)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.76)	18.2507
2000's	12 (9.16)	29.6817
2010's	90 (68.70)	24.3611
2020's	28 (21.37)	2.80

Authors

Authors	Studies
Hansen, E; Xu, K	1
Aguilar, C; Arzuaga, J; Bernal, T; Borrás, J; Brunet, S; Calabuig, M; Calbacho, M; Cedena, MT; Chen, TH; Coll, R; Collado, R; Cortés, M; Díaz-Beyá, M; Fernández, M; García, O; Jiménez, MJ; López-Cadenas, F; Marchante, I; Marco, V; Medina, A; Pedreño, M; Pedró, C; Ramos, F; Ribera, JM; Sanz, G; Simiele, A; Stoica, C; Talarn, C; Triguero, A; Xicoy, B; Zamora, L	1
Adès, L; Anagnostopoulos, A; De Paz Arias, R; Díez-Campelo, M; Doronin, VA; Faller, DV; Fram, RJ; Friedlander, S; Girshova, L; Kambhampati, S; Munhoz, EC; Platzbecker, U; Santini, V; Sekeres, MA; Symeonidis, A; Valcárcel, D; Viniou, NA; Woszczyk, D; Yuan, Y	1
Guo, R; Jin, J; Lan, J; Miao, M; Xu, Y; Zhang, G	1
Akiyama, H; Hagino, T; Hidai, H; Motomura, S; Murai, Y; Saga, R; Sato, T	1
Chien, KS; Darbaniyan, F; Daver, N; Do, KA; Ganan-Gomez, I; Garcia-Manero, G; Kanagal-Shamanna, R; Li, Z; Lockyer, PP; Montalban-Bravo, G; Soltysiak, KA; Wei, Y; Yang, H; Zheng, H	1
Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M	1
Ades, L; Banos, A; Bezanahary, H; Chermat, F; Chevret, S; Comont, T; D'Aveni Piney, M; De Renzis, B; Denis, G; Desseaux, K; Diaz, JMT; Dimicoli-Salazar, S; Durot, E; Fain, O; Fenaux, P; Frenzel, L; Gourin, MP; Grobost, V; Gyan, E; Himberlin, C; Hirsch, P; Jachiet, V; Kosmider, O; Lemaire, K; Maria, A; Mekinian, A; Natarajan-Amé, S; Pascal, L; Peterlin, P; Rauzy, OB; Terriou, L; Thépot, S; Vey, N; Voillat, L; Wickenhauser, S; Zhao, LP	1
Chien, KS; Class, C; Darbaniyan, F; Do, KA; Estecio, M; Ganan-Gomez, I; Garcia-Manero, G; Kanagal-Shamanna, R; Lockyer, P; Lu, Y; Montalban-Bravo, G; Sasaki, K; Soltysiak, KA; Wei, Y; Yang, H; Zheng, H	1
Geissler, K; Reiser, J	1
Asch, AS; Assouline, S; Cheema, F; Erba, HP; Fang, M; Hay, AE; Jacoby, MA; Kingsbury, LL; Law, LY; Little, RF; Liu, JJ; Maher, T; Michaelis, LC; Moseley, AB; Othus, M; Radich, J; Schroeder, MA; Sweet, KL; Uy, GL; Walter, RB	1
Demir, AM; Demirci, U; Iflazoglu, H; Kirkizlar, O; Kirkizlar, TA; Umit, EG; Umut, A	1
Al-Kali, A; Bogenberger, J; Dueck, AC; Hashmi, S; Hogan, W; Kosiorek, HE; Litzow, MR; Mesa, R; Palmer, J; Sproat, L; Tibes, R	1
Giagounidis, A; Hertle, S; Hoef, MV; Ma, F; Santini, V; Sanz, GF; Sekeres, MA; Xiao, Z; Zeidan, AM	1
Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R	1
Chasset, F; Fain, O; Fenaux, P; Hadjadj, J; Jachiet, V; Mekinian, A; Zhao, LP	1
Bailey, R; Beach, CL; Gaudy, A; Laille, E; Skikne, B; Zhou, S	1
Ernst, T; Gawlitza, AL; Hochhaus, A; Müller, EK; Rinke, J; Sajzew, R; Schäfer, V; Speith, J	1
Attig, J; Bernard, E; Kassiotis, G; Kazachenka, A; Kordella, C; Kotsianidis, I; Lamprianidou, E; Papaemmanuil, E; Papoutselis, M; Vrachiolias, G; Young, GR; Zoulia, E	1
Adams, FF; Alwie, Y; Gabdoulline, R; Ganser, A; Gupta, C; Heckl, D; Heuser, M; Humphries, RK; Imren, S; Jyotsana, N; Kattre, N; Kloos, A; Mintzas, K; Schambach, A; Scherr, M; Schottmann, R; Schwarzer, A; Thol, F; Winckler, L	1
Fu, L; Hu, L; Hu, M; Zheng, B	1
Bachmaier, G; Berg, JL; Berghold, A; Geissler, K; Hatzl, S; Hoefler, G; Klymiuk, I; Mayer, MC; Perfler, B; Pichler, M; Pregartner, G; Reinisch, A; Sill, H; Strobl, H; Tierling, S; Uhl, B; Wölfler, A; Wurm, S; Zebisch, A	1
Garcia-Horton, A; Gupta, V; Maze, D; McNamara, CJ; Murphy, T; Sibai, H	1
Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D	1
Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X	1
Arnan, M; Avendaño Pita, A; Bernal Del Castillo, T; Bonadies, N; Calabuig Muñoz, M; Cermak, J; Cortés, A; Dimou, M; Egle, A; Galanopoulos, A; Geissler, K; Germing, U; Greil, R; Heibl, S; Hellstroem-Lindberg, E; Hunter, AM; Jerez, A; Jimenez Lorenzo, MJ; Kaivers, J; Kourakli, A; Larcher-Senn, J; Leisch, M; List, AF; Lopez Andrade, B; Maciejewski, JP; Medina de Almeida, A; Melchardt, T; Montoro, MJ; Mora, E; Padron, E; Patel, BJ; Patiou, P; Pleyer, L; Roubakis, C; Sanz, GF; Sekeres, MA; Symeonidis, A; Ungerstedt, J; Valent, P; Viniou, AN; Xicoy Cirici, B	1
Anasetti, C; Bejanyan, N	1
Deng, C; Du, X; Geng, S; Huang, X; Li, M; Weng, J; Wu, P; Xu, R	1
Bewersdorf, JP; Johnson, A; Lee, J; Schiffer, M; Zeidan, AM; Zhao, J	1
Cahill, K; Odenike, O; Patel, AA; Saygin, C	1
Alessandrino, EP; Candoni, A; Carella, AM; Cerqui, E; Cortelezzi, A; Criscuolo, M; Fianchi, L; Finelli, C; Leone, G; Masciulli, A; Molteni, A; Parma, M; Piciocchi, A; Poloni, A; Rambaldi, A; Salvi, F; Santarone, S; Sica, S; Spina, F; Voso, MT	1
Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y	1
Beyne-Rauzy, O; Braun, T; Chait, Y; Chretien, ML; Duchmann, M; Dumas, PY; Fenaux, P; Gruson, B; Guieze, R; Hirsch, P; Itzykson, R; Laribi, K; Legros, L; Micol, JB; Park, S; Pilorge, S; Platzbecker, U; Sahnes, L; Salanoubat, C; Sébert, M; Solary, E; Vey, N	1
Acharyya, S; Borbenyi, Z; Breccia, M; Cavenagh, JD; DeAngelo, DJ; Egyed, M; Fenaux, P; Garcia-Manero, G; Gazi, L; Graux, C; Ide, S; Illes, A; Lee, JH; MacWhannell, A; Marker, M; Ottmann, OG; Salman, H; Sekeres, MA; Stauder, R; Valcarcel, D; Yee, K; Zhu, N	1
Craddock, C	1
Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Long, JB; Ma, X; Podoltsev, NA; Wang, R; Zeidan, AM	1
Abruzzese, E; Caravita, T; Cupelli, L; de Fabritiis, P; Giovannini, M; Niscola, P; Scaramucci, L; Siniscalchi, A; Tendas, A; Trawinska, MM	1
Kobayashi, T; Kobayashi, Y; Matsuoka, F; Minami, H; Munakata, W; Ogura, M; Shimada, F; Tajima, T; Taniwaki, M; Uchida, T; Yakushijin, K; Yonemura, M	1
Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C	1
Ballanti, S; Calabrese, G; Canino, S; Di Bartolomeo, P; Di Battista, V; Matteucci, C; Mecucci, C; Moretti, M; Pulini, S; Quintini, M	1
Ades, L; Bally, C; Bergeron, A; Burns, R; Fenaux, P; Hilmi, M; Lorillon, G	1
Bertsch, HP; Claßen, A; Kitz, J; Lippert, U; Overbeck, T; Perske, C; Schön, MP	1
Abisror, N; Deligny, C; Droin, N; Fain, O; Martin, A; Mekinian, A; Ricard, L; Selimoglu-Buet, D; Solary, E; Soussan, M; Willekens, C	1
Burgstaller, S; Egle, A; Faber, V; Geissler, K; Greil, R; Huemer, F; Lang, A; Machherndl-Spandl, S; Neureiter, D; Pfeilstöcker, M; Pichler, A; Pleyer, L; Sperr, W; Stampfl, M; Stauder, R; Voskova, D; Weiss, L; Zebisch, A	1
Behrens, YL; Göhring, G; Lentes, J; Rothe, D; Schlegelberger, B; Steinemann, D; Thomay, K; Wittig, V; Wittner, N	1
Aubanel, S; Boué, Y; Dartevel, A; Fauché, C; Faurie, P; Peigne, V; Pica, GM	1
Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM	1
Hannig, CV; Harde, J; Harich, HD; Klausmann, M; Losem, C; Müller, J; Niemeier, B; Potthoff, K; Schmitz, S; Tessen, HW; Wehmeyer, J; Zaiss, M	1
Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A	1
Hunter, AM; Padron, E; Zhang, L	1
Armatys, A; Boral, K; Chromik, K; Dworaczek, M; Helbig, G; Koclęga, A; Kopińska, AJ; Markiewicz, M; Panz-Klapuch, M; Woźniczka, K	1
Lebecque, B; Lechevalier, N; Pigneux, A; Vial, JP	1
Grigoriadis, G; Tedjaseputra, A; Vilcassim, FS	1
Duchmann, M; Itzykson, R	1
Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E	1
Adès, L; Dreyfus, F; Fenaux, P; Itzykson, R; Komrokji, RS; List, AF; Maciejewski, JP; Sekeres, MA; Teichman, ML; Tiu, RV; Wolfromm, A	1
Almeida, A	1
Germing, U; Neukirchen, J	1
Bastian, L; Haberthür, R; Menter, T; Rätz Bravo, AE; Schlageter, M; Tzankov, A	1
Beijnen, JH; Derissen, EJ; Schellens, JH	1
Parikh, SA; Tefferi, A	2
Gaikazian, S; Kumar, R; Shah, D	1
Bueso-Ramos, C; Cortes, J; Davanlou, M; DiNardo, C; Estecio, MR; Fang, Z; Garcia-Manero, G; Geng, QR; Kantarjian, H; Nguyen, M; Parmar, S; Pierce, S; Wei, Y; Yang, H	1
Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K	1
Prada Garcia, C; Rodriguez Prieto, MÁ; Sanchez Sambucety, P	1
Alhan, C; Buchi, F; Eeltink, C; Huls, G; Ossenkoppele, GJ; Santini, V; van de Loosdrecht, AA; van der Helm, LH; Westers, TM; Witte, BI	1
Burgstaller, S; Geissler, D; Germing, U; Girschikofsky, M; Greil, R; Lang, A; Linkesch, W; Mitrovic, M; Neureiter, D; Pfeilstocker, M; Placher-Sorko, G; Pleyer, L; Schlick, K; Schreder, M; Sliwa, T; Sperr, WR; Stauder, R; Thaler, J; Theiler, G; Valent, P	1
Boissinot, M; Bowen, DT; Brown, J; Cauchy, P; Cockerill, PN; Cross, NC; Drummond, MW; Hartley, S; Kell, J; Mills, J; Pocock, C; Szubert, A	1
Almeida, AM	1
Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS	1
Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Takakuwa, T	1
Cupelli, L; de Fabritiis, P; Del Poeta, G; Dentamaro, T; Giovannini, M; Niscola, P; Piccioni, D; Scaramucci, L; Tendas, A	1
Bruneau, J; Cheminant, M; Delarue, R; Derrieux, C; Gaulard, P; Hermine, O; Kosmider, O; Lefrere, F; Lemonnier, F; Radford, I	1
Glasmacher, A; Meers, S; Mineur, P; Potier, H; Selleslag, D; Voelter, V	1
Beguin, Y; Bries, G; Deeren, D; Graux, C; Meers, S; Mineur, P; Noens, L; Potier, H; Ravoet, C; Selleslag, D; Theunissen, K; Trullemans, F; Voelter, V; Vrelust, I	1
Adès, L; Berthon, C; Braun, T; Brechignac, S; Cherait, A; Fenaux, P; Gardin, C; Harel, S; Park, S; Quesnel, B; Rigal, M; Thépot, S; Willekens, C	1
Abdel-Wahab, O; Allione, B; Buchi, F; Droin, N; Figueroa, ME; Gioia, D; Lunghi, M; Masala, E; Meldi, K; Micol, JB; Poloni, A; Qin, T; Santini, V; Selimoglu-Buet, D; Solary, E; Sotzen, J	1
Friis, LS; Grønbæk, K; Hokland, M; Holm, MS; Skovbo, A; Treppendahl, MB; Ørskov, AD	1
Caravita, T; de Fabritiis, P; Fratoni, S; Niscola, P; Scaramucci, L; Siniscalchi, A; Tendas, A	1
Cogle, CR; Garcia-Manero, G; Gore, SD; Hetzer, J; Kumar, K; Laille, E; MacBeth, KJ; Shi, T; Skikne, B	1
Adès, L; Amoura, Z; Braun, T; Buchdaul, AL; Cathebras, P; Costedoat-Chalumeau, N; De Wazieres, B; Decaux, O; Denis, G; Dion, J; Fain, O; Falgarone, G; Fenaux, P; Gardin, C; Georgin-Lavialle, S; Gombert, B; Grignano, E; Hamidou, M; Kahn, JE; Launay, D; Lioger, B; Liozon, E; Lortholary, O; Madaule, S; Mathian, A; Mekinian, A; Montestruc, F; Morel, N; Nimubona, S; Omouri, M; Park, S; Piette, JC; Puéchal, X; Raffray, L; Rose, C; Rossignol, J; Schoindre, Y; Toussirot, E; Trouiller, S; Ziza, JM	1
Al-Kali, A; Alfakara, D; Hashmi, S; Hogan, W; Hook, C; Litzow, M; Patnaik, M; Subari, S; Zblewski, D	1
Dao, KH; Deininger, MW; Kelley, TW; Khorashad, JS; Kovacsovics, T; Szankasi, P; Tantravahi, SK	1
Berkovits, A; Cantó, G; Diocares, G; López, A; Zelada, J	1
Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R	1
Alexandrov, LB; Artiguenave, F; Auboeuf, D; Bernard, O; Braun, T; Chautard, E; Commes, T; Cowley, MJ; de Botton, S; Deleuze, JF; Dinger, ME; Droin, N; Fenaux, P; Figueroa, M; Gayevskiy, V; Itzykson, R; Jourdan, E; Koscielny, S; Meldi, K; Merlevede, J; Meyer, V; Morabito, M; Ogawa, S; Padron, E; Pata-Merci, N; Preudhomme, C; Qin, T; Quesnel, B; Selimoglu-Buet, D; Solary, E; Solier, S; Stratton, MR; Vainchenker, W; Yoshida, K	1
Cowan, L; Filshie, R; Hertzberg, M; Ho, SJ; Kenealy, M; Link, E; Mills, T; Nicol, A; Patton, N; Prosser, I; Seymour, JF; Zannino, D	1
Asnafi, V; Bruneau, J; Cheminant, M; Couronne, L; Delarue, R; Derrieux, C; Frenzel, L; Guermouche, H; Hermine, O; Kosmider, O; Lemonnier, F; Lhermitte, L; Macintyre, E; Molina, T; Saillard, C; Suarez, F; Trinquand, A	1
Gomes de Souza, VH; Moura, CA; Moura, CG; Neto, J; Santiago, M	1
Cermak, J; Hajkova, H; Jonasova, A; Klema, J; Merkerova, MD; Monika Belickova, M; Pejsova, B; Valka, J; Vesela, J; Votavova, H	1
Alfonso, A; Garcia-Manero, G; Montalban-Bravo, G	1
Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L	1
Ahmed, F; Bennett, JM; Komrokji, RS; Lucas, F; Neff, G; Osman, N; Smolarek, T	1
Alsina, M; Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Huang, Y; Janssen, W; Kharfan-Dabaja, MA; Lancet, J; List, A; Perez, L; Perkins, J; Sullivan, D	1
Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R	1
Becker, PS; Deeg, HJ; Estey, EH; Petersdorf, S; Ramakrishnan, A; Scott, BL; Storer, B	1
Connock, M; Edlin, R; Fry-Smith, A; Greenheld, W; Hyde, C; Round, J; Tubeuf, S	1
Batty, GN; Cortés, JE; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; McCue, D; O'Brien, S; Pierce, S; Ravandi, F; Santos, FP	1
Batty, N; Cortes, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J	1
Basquiera, A; Bernard, HI; Iastrebner, M; Jang, JH; Jung, CW; Kim, DH; Kim, K; Klein, G; Korin, J; Nucifora, E; Orlando, S; Sackmann, F; Santini, F; Taborda, G	1
Aucagne, R; Bastie, JN; Bataille, A; Delva, L; Droin, N; Fenaux, P; Hammann, A; Lagrange, B; Largeot, A; Losson, R; Martin, L; Paggetti, J; Solary, E; Yan, KP	1
Cogle, C; Garcia-Manero, G; Giordano, H; Gore, SD; Jabbour, E; Kantarjian, H; Laille, E; Macbeth, KJ; Sakoian, S; Shi, T; Skikne, B; Ward, R	1
George, E; Holden, J; Miller, W; Stein, K	1
Abdulhaq, H; Atem, FD; Costa, R; Haq, B; Latsko, J; Lister, J; Rossetti, JM; Sahovic, EA; Shadduck, RK; Zenati, M	1
Ades, L; Bouabdallah, K; Braun, T; de Renzis, B; Dreyfus, F; Droin, N; Fenaux, P; Fontenay, M; Gardin, C; Itzykson, R; Joly, B; Lafon, I; Laribi, K; Meurice, G; Oréar, C; Preudhomme, C; Recher, C; Renneville, A; Royer, B; Sanhes, L; Solary, E; Toma, A; Vekhoff, A; Vey, N	1
Badens, C; Charpentier, A; Fournier, M; Herbaux, C; Nibourel, O; Pissard, S; Preudhomme, C; Renneville, A; Rose, C	1
Alhan, C; Beeker, A; Biemond, BJ; Brouwer, RE; Croon-de Boer, F; de Weerdt, O; Eefting, M; Hoogendoorn, M; Huls, G; Jie, KS; Koedam, J; Libourel, WJ; Luykx-de Bakker, SA; Minnema, MC; Schaafsma, R; van de Loosdrecht, AA; van der Helm, LH; van Marwijk Kooy, M; van Rees, BP; Veeger, NJ; Vellenga, E; Wegman, J; Wijermans, PW	1
Wang, HX; Wang, L; Zhao, J	1
Guijarro-Llorca, J; Toledo-Alberola, F	1
Craig, M; Cumpston, A; Trickett, HB	1
Almeida, A; Moita, F; Montalvão, A; Pierdomenico, F; Thorpe, M	1
Almeida, AM; Pierdomenico, F	1
Alimena, G; Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Zacheo, I	1
Aloe-Spiriti, A; Breccia, M; Criscuolo, M; Fianchi, L; Finelli, C; Gaidano, G; Greco, M; Hohaus, S; Leone, G; Mansueto, G; Maurillo, L; Musto, P; Salvi, F; Santini, V; Voso, MT	1
Dickinson, M; Herbert, K; Kenealy, M; Seymour, JF; Westerman, D; Wong, E	1
Alimena, G; Breccia, M; Voso, MT	1
Do, YR; Huh, J; Kim, DD; Kim, H; Kim, HJ; Kim, KH; Kim, MK; Kim, SH; Kim, T; Mun, YC; Yi, JH	1
Alimena, G; Bari, A; Breccia, M; Fianchi, L; Finelli, C; Leone, G; Lunghi, M; Musto, P; Niscola, P; Poloni, A; Voso, MT; Zambello, R	1
Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A	1
Bueso-Ramos, C; Cortes, J; Davis, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Huang, X; Issa, JP; Kantarjian, H; O'Brien, S; Oki, Y; Ravandi, F; Saba, HI; Shan, J; Wierda, W	1
Aribi, A; Borthakur, G; Cortes, J; Davisson, J; Kantarjian, H; Ravandi, F; Shan, J	1
Steensma, DP; Tefferi, A	1
Giagounidis, AA	1
Friday, BB; Steensma, DP	1
Baer, MR; Lübbert, M; Rüter, B; Saba, HI; Slack, JL; Wijermans, PW	1
Issa, JP; Jelinek, J; Kantarjian, HM; Oki, Y; Shen, L	1
Gore, SD; Griffiths, EA	1
Hinckley, MR; Molnár, I; Sangueza, OP; Sheehan, DJ; Walsh, SN; Yosipovitch, G	1
Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW	1
Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P	1

Reviews

17 review(s) available for azacitidine and Leukemia, Myelomonocytic, Chronic

Article	Year
Novel agents for myelodysplastic syndromes. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8 Topics: Azacitidine; Decitabine; Drug Approval; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; United States Food and Drug Administration	2021
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England), 2023, Volume: 19, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes	2023
[Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias]. Bulletin du cancer, 2023, Volume: 110, Issue:11 Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Skin Diseases	2023
Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report. Medicine, 2020, Oct-30, Volume: 99, Issue:44 Topics: Adult; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Pleural Effusion; Tomography, X-Ray Computed	2020
Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Treatment Outcome	2021
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood advances, 2021, 04-27, Volume: 5, Issue:8 Topics: Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine	2021
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. Current treatment options in oncology, 2018, 10-27, Volume: 19, Issue:12 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myelomonocytic, Chronic; Transplantation, Homologous	2018
Clinical update on hypomethylating agents. International journal of hematology, 2019, Volume: 110, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Combinations; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine	2019
A systematic review and meta Hematology (Amsterdam, Netherlands), 2019, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2019
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. American journal of hematology, 2013, Volume: 88, Issue:11 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decision Trees; Decitabine; Diagnosis, Differential; DNA Methylation; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytosis; Monocytes; Mutation; Practice Guidelines as Topic; Prognosis	2013
Current management of patients with chronic myelomonocytic leukemia. Current opinion in oncology, 2017, Volume: 29, Issue:1 Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Stem Cell Transplantation	2017
Therapy related CMML: a case report and review of the literature. International journal of hematology, 2009, Volume: 89, Issue:5 Topics: Azacitidine; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Chronic; Liver Failure, Acute; Liver Transplantation; Young Adult	2009
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Models, Economic; Myelodysplastic Syndromes; Quality of Life; Quality-Adjusted Life Years; Survival; United Kingdom	2010
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leukemia research, 2012, Volume: 36, Issue:8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Treatment Outcome	2012
Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. American journal of hematology, 2012, Volume: 87, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Examination; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Diagnosis, Differential; Disease Management; Female; Genes, Neoplasm; Humans; Leukemia, Myelomonocytic, Chronic; Leukocyte Count; Male; Risk Assessment; Stem Cell Transplantation; Transplantation, Homologous	2012
Risk-based management of myelodysplastic syndrome. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1 Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles	2007
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in hematology, 2008, Volume: 45, Issue:1 Topics: Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes	2008

Trials

27 trial(s) available for azacitidine and Leukemia, Myelomonocytic, Chronic

Article	Year
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood advances, 2022, 09-13, Volume: 6, Issue:17 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Drug Therapy, Combination; Humans; Leukemia, Myelomonocytic, Chronic; Pyrimidines	2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. The Lancet. Haematology, 2022, Volume: 9, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Sulfonamides	2022
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia, 2022, Volume: 36, Issue:11 Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prospective Studies; Steroids	2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the Leukemia & lymphoma, 2023, Volume: 64, Issue:2 Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Nivolumab	2023
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer, 2023, 08-01, Volume: 129, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Treatment Outcome	2023
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 2021, Volume: 35, Issue:7 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines	2021
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. Clinical and translational science, 2021, Volume: 14, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States	2021
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Aug-20, Volume: 35, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat	2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts. Leukemia, 2017, Volume: 31, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome	2017
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. International journal of hematology, 2018, Volume: 107, Issue:1 Topics: Aged; Asian People; Azacitidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome	2018
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. American journal of hematology, 2018, Volume: 93, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fatigue; Female; Food; Food-Drug Interactions; Gastric Acidity Determination; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Proton Pump Inhibitors	2018
Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm. British journal of haematology, 2019, Volume: 185, Issue:3 Topics: Aged; Antigens, CD; Azacitidine; Dendritic Cells; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Neoplasm Proteins	2019
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leukemia research, 2013, Volume: 37, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Pharmacological; Biomarkers, Tumor; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis	2013
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia, 2014, Volume: 28, Issue:7 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Treatment Outcome	2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-20, Volume: 32, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyridines; Survival Analysis; Treatment Outcome	2014
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. The Journal of clinical investigation, 2015, Volume: 125, Issue:5 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; beta-Thromboglobulin; Bone Marrow; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Intergenic; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Neoplasm Proteins; Platelet Factor 4; Treatment Outcome	2015
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PloS one, 2015, Volume: 10, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis	2015
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leukemia & lymphoma, 2016, Volume: 57, Issue:10 Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers, Pharmacological; Biomarkers, Tumor; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Survival Analysis; Treatment Outcome	2016
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia & lymphoma, 2017, Volume: 58, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Neoplasm Staging; Quality of Health Care; Survival Analysis; Thalidomide; Treatment Outcome	2017
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. British journal of haematology, 2010, Volume: 148, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome	2010
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leukemia & lymphoma, 2010, Volume: 51, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Argentina; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Republic of Korea; Survival Analysis; Treatment Outcome; Young Adult	2010
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; DNA Methylation; Fatigue; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia	2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 2011, Oct-06, Volume: 118, Issue:14 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Prognosis; Survival Analysis	2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p British journal of haematology, 2011, Volume: 155, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Platelets; Cohort Studies; Compassionate Use Trials; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Netherlands; Retrospective Studies; Survival Analysis; Treatment Outcome	2011
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, Jan-01, Volume: 109, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bayes Theorem; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Risk; Treatment Outcome	2007
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood, 2008, Feb-15, Volume: 111, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Janus Kinase 2; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction	2008

Other Studies

87 other study(ies) available for azacitidine and Leukemia, Myelomonocytic, Chronic

Article	Year
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Leukemia research, 2022, Volume: 116 Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Retrospective Studies	2022
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study. Investigational new drugs, 2022, Volume: 40, Issue:5 Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome	2022
Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia. International journal of hematology, 2022, Volume: 116, Issue:6 Topics: Aged, 80 and over; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Leukemoid Reaction; Leukocytosis; Male	2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & lymphoma, 2022, Volume: 63, Issue:13 Topics: Animals; Azacitidine; Imidazoles; Leukemia, Myelomonocytic, Chronic; Mice; Myelodysplastic Syndromes	2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Experimental hematology, 2022, Volume: 115 Topics: Animals; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Mice; Myelodysplastic Syndromes; Transcriptome	2022
Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia. Wiener medizinische Wochenschrift (1946), 2023, Volume: 173, Issue:1-2 Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Retrospective Studies	2023
Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leukemia research, 2023, Volume: 127 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Causality; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica, 2023, 11-01, Volume: 108, Issue:11 Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous	2023
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia. Clinical pharmacology and therapeutics, 2023, Volume: 114, Issue:4 Topics: Adult; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes	2023
5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. Journal of cancer research and clinical oncology, 2019, Volume: 145, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Case-Control Studies; CpG Islands; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Receptor, Notch1; Tumor Cells, Cultured	2019
Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression. Genome medicine, 2019, 12-23, Volume: 11, Issue:1 Topics: Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Carrier Proteins; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Differentiation; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Mannosyltransferases; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retroelements; Transcriptome; Treatment Failure; Tumor Suppressor Proteins	2019
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, 2020, Volume: 34, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clonal Evolution; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; GTP Phosphohydrolases; Humans; Leukemia, Myelomonocytic, Chronic; Membrane Proteins; Mice; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Receptor, Notch1; RNA, Small Interfering; Xenograft Model Antitumor Assays	2020
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. Clinical epigenetics, 2021, 01-06, Volume: 13, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Models, Animal; DNA Methylation; Gene Expression Regulation; Genome-Wide Association Study; Humans; Leukemia, Myelomonocytic, Chronic; Mice; RNA, Messenger	2021
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series. Leukemia & lymphoma, 2021, Volume: 62, Issue:6 Topics: Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myelomonocytic, Chronic; Sulfonamides	2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. The Lancet. Haematology, 2021, Volume: 8, Issue:2 Topics: Aged; Antineoplastic Agents; Azacitidine; Female; Humans; Hydroxyurea; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2021
First-line hypomethylating agents for patients with high risk chronic myelomonocytic leukaemia. The Lancet. Haematology, 2021, Volume: 8, Issue:2 Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Retrospective Studies	2021
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. Expert review of anticancer therapy, 2021, Volume: 21, Issue:9 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes	2021
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood cancer journal, 2017, 05-12, Volume: 7, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Survival Analysis; Treatment Outcome	2017
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 08-20, Volume: 35, Issue:24 Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; Vorinostat	2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. Cancer, 2017, Oct-01, Volume: 123, Issue:19 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Medicare; Propensity Score; Proportional Hazards Models; Retrospective Studies; SEER Program; United States	2017
Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. Annals of hematology, 2017, Volume: 96, Issue:9 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Follow-Up Studies; Frail Elderly; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. Medicine, 2017, Volume: 96, Issue:43 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome	2017
Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment. European journal of dermatology : EJD, 2017, 10-01, Volume: 27, Issue:5 Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Lip Neoplasms; Male; Middle Aged; Skin Neoplasms	2017
Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. Annals of hematology, 2018, Volume: 97, Issue:3 Topics: Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Drug Resistance; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Lung Diseases, Interstitial; Male; Middle Aged; Oxygen Inhalation Therapy; Prednisone; Tomography, X-Ray Computed	2018
Leukemia cutis in a patient with chronic myelomonocytic leukemia. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:1 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Diagnosis, Differential; Humans; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Skin	2018
Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Antimetabolites, Antineoplastic; Azacitidine; Dioxygenases; DNA-Binding Proteins; Exome Sequencing; Female; Hematopoiesis, Extramedullary; Humans; Leukemia, Myelomonocytic, Chronic; Lipopolysaccharide Receptors; Magnetic Resonance Imaging; Middle Aged; Monocytes; Multimodal Imaging; Mutation; Positron-Emission Tomography; Proto-Oncogene Proteins; Retroperitoneal Fibrosis	2018
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener klinische Wochenschrift, 2018, Volume: 130, Issue:3-4 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Time Factors	2018
Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Aged; Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 21; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; GTP Phosphohydrolases; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Membrane Proteins; Neoplasms, Second Primary	2018
[Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine]. La Revue de medecine interne, 2018, Volume: 39, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Hemophilia A; Humans; Leukemia, Myelomonocytic, Chronic; Rituximab; Treatment Outcome	2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). European journal of haematology, 2018, Volume: 101, Issue:6 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2018
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study. Transplantation proceedings, 2018, Volume: 50, Issue:7 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult	2018
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. Pathology oncology research : POR, 2019, Volume: 25, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Safety; Survival Rate; Treatment Outcome	2019
Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with BMJ case reports, 2019, Mar-31, Volume: 12, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Exophthalmos; Fatal Outcome; Humans; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Mutation; Proto-Oncogene Proteins B-raf; Retina; Retinal Diseases	2019
Modifying disease in CMML: who responds to Azacitidine? Leukemia research, 2013, Volume: 37, Issue:6 Topics: Azacitidine; Biomarkers, Pharmacological; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male	2013
How to treat patients with CMML? Leukemia research, 2013, Volume: 37, Issue:6 Topics: Azacitidine; Biomarkers, Pharmacological; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male	2013
Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia. Hematological oncology, 2014, Volume: 32, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Bone Marrow; Combined Modality Therapy; Disease Progression; Epstein-Barr Virus Infections; Fatal Outcome; Female; Humans; Iatrogenic Disease; Leukemia, Myelomonocytic, Chronic; Lung; Lymph Nodes; Lymphoproliferative Disorders; Necrosis; Pneumonia; RNA, Viral; Spleen; Viral Matrix Proteins	2014
Concise drug review: azacitidine and decitabine. The oncologist, 2013, Volume: 18, Issue:5 Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Approval; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes	2013
A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine. Haemophilia : the official journal of the World Federation of Hemophilia, 2014, Volume: 20, Issue:1 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hemophilia A; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Treatment Outcome	2014
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia, 2014, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers, Tumor; Cohort Studies; CTLA-4 Antigen; Decitabine; DNA Methylation; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured	2014
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. International journal of hematology, 2014, Volume: 99, Issue:2 Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome	2014
[Cutaneous infiltratiton by chronic myelononocytic leukemia: presentation of three cases]. Dermatology online journal, 2013, Nov-15, Volume: 19, Issue:11 Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Fatal Outcome; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Skin	2013
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry. Part B, Clinical cytometry, 2014, Volume: 86, Issue:3 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Pharmacological; Bone Marrow Cells; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Prognosis; Research Design; Retrospective Studies; Risk Factors	2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia research, 2014, Volume: 38, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Matched-Pair Analysis; Middle Aged; Survival Analysis	2014
Optimizing treatments in rare diseases: will our evidence come from registry data? Leukemia research, 2014, Volume: 38, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male	2014
[Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 20; Humans; Leukemia, Myelomonocytic, Chronic; Male; Treatment Outcome	2014
Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta haematologica, 2015, Volume: 133, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Failure	2015
Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. British journal of haematology, 2015, Volume: 168, Issue:6 Topics: Aged; Antineoplastic Agents; Azacitidine; Dioxygenases; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Female; Humans; Immunoblastic Lymphadenopathy; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Mutation; Proto-Oncogene Proteins	2015
Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia. Current medical research and opinion, 2015, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Health Services Accessibility; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Reimbursement Mechanisms	2015
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Acta clinica Belgica, 2015, Volume: 70, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Treatment Outcome	2015
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia research, 2015, Volume: 39, Issue:5 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome	2015
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget, 2015, Apr-20, Volume: 6, Issue:11 Topics: Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Blood Cells; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Activation; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; T-Lymphocyte Subsets	2015
Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders. Annals of hematology, 2015, Volume: 94, Issue:10 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Paraproteinemias; Treatment Outcome	2015
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Autoimmunity; Azacitidine; Drug Therapy, Combination; Female; Follow-Up Studies; France; Glucocorticoids; Humans; Inflammation; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies	2016
Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leukemia & lymphoma, 2016, Volume: 57, Issue:7 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Retrospective Studies; Splenomegaly; Treatment Outcome	2016
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case]. Revista medica de Chile, 2015, Volume: 143, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Factor X Deficiency; Frontal Lobe; Hematoma; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytes; Male; Monocytes; Seizures	2015
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:6 Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature communications, 2016, Feb-24, Volume: 7 Topics: Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Sequence Analysis, DNA; Sequence Analysis, RNA	2016
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. Hematological oncology, 2017, Volume: 35, Issue:4 Topics: Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Lymphoma, B-Cell; Lymphoma, T-Cell	2017
Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus. Lupus, 2017, Volume: 26, Issue:2 Topics: Aged, 80 and over; Antibodies, Antinuclear; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Examination; Diagnosis, Differential; Female; Hemolysis; Humans; Leukemia, Myelomonocytic, Chronic; Lupus Erythematosus, Systemic; Predictive Value of Tests; Thrombocytopenia	2017
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. International journal of hematology, 2016, Volume: 104, Issue:5 Topics: Azacitidine; Bone Marrow Cells; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ribosomal Proteins; Transcriptome; Treatment Failure; Up-Regulation	2016
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib. Cancer biology & therapy, 2017, Nov-02, Volume: 18, Issue:11 Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib	2017
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Adult; Aged; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2010
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone marrow transplantation, 2010, Volume: 45, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous	2010
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Kaplan-Meier Estimate; Kidney; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Renal Insufficiency	2010
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 2010, Aug-15, Volume: 116, Issue:16 Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Treatment Failure; Treatment Outcome	2010
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. The Journal of clinical investigation, 2011, Volume: 121, Issue:6 Topics: Aged; Aged, 80 and over; Aging; Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Differentiation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myelomonocytic, Chronic; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Receptor, Macrophage Colony-Stimulating Factor; Specific Pathogen-Free Organisms; Transcription Factors	2011
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. The Lancet. Oncology, 2011, Volume: 12, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality-Adjusted Life Years	2011
Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 2011, Jun-15, Volume: 117, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Retrospective Studies	2011
Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy. Leukemia research, 2011, Volume: 35, Issue:11 Topics: Aged; alpha-Thalassemia; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Evolution, Molecular; Fatal Outcome; Humans; Leukemia, Myelomonocytic, Chronic; Male; Syndrome	2011
[Treatment of two chronic myelomonocytic leukemia patients with Decitabine]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic	2011
Rapidly growing ulcer in a patient with neurofibromatosis type I. Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:1 Topics: Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Humans; Hypothyroidism; Immunocompromised Host; Leg Ulcer; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neoplasms, Second Primary; Neurofibromatosis 1; Pheochromocytoma; Pseudomonas Infections; Staphylococcal Infections	2012
Azacitidine-associated Sweet's syndrome. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, May-15, Volume: 69, Issue:10 Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Drug Eruptions; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Sweet Syndrome	2012
Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone. Leukemia research, 2012, Volume: 36, Issue:9 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Exanthema; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Prednisolone; Treatment Outcome	2012
Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. Leukemia & lymphoma, 2013, Volume: 54, Issue:2 Topics: Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Sarcoma, Myeloid; Treatment Outcome	2013
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Italy; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome	2013
Treatment of chronic myelomonocytic leukemia with azacitidine. Leukemia & lymphoma, 2013, Volume: 54, Issue:4 Topics: Azacitidine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male	2013
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? Leukemia research, 2013, Volume: 37, Issue:2 Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic	2013
Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Annals of hematology, 2013, Volume: 92, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Mapping; Decitabine; Drug Resistance, Neoplasm; Female; Genome, Human; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Microarray Analysis; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome	2013
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. European journal of haematology, 2013, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies	2013
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome	2006
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer, 2007, Feb-15, Volume: 109, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; DNA Modification Methylases; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Survival Rate; Treatment Outcome	2007
Decitabine dosage in myelodysplastic syndromes. Blood, 2007, Aug-01, Volume: 110, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome	2007
Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leukemia & lymphoma, 2007, Volume: 48, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Humans; Leukemia, Myelomonocytic, Chronic; Monocytes; Skin Diseases	2007
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia research, 2008, Volume: 32, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2008
Generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia: a report of 2 cases. The American Journal of dermatopathology, 2008, Volume: 30, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Diagnosis, Differential; Fatal Outcome; Granuloma Annulare; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; PUVA Therapy	2008
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia, 1997, Volume: 11, Issue:1 Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia	1997
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British journal of haematology, 2001, Volume: 114, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate	2001